Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Similar documents
PANCREATIC ISLET TRANSPLANT

ENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER

IMMUNE CELL FUNCTION ASSAY

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

GENETIC TESTING FOR TAMOXIFEN TREATMENT

RADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS

GENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES

PROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

LARTRUVO (olaratumab)

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

NEGATIVE PRESSURE WOUND THERAPY

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER

RADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS

BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

ORAL IMPLANT PROCEDURES

GENETIC TESTING FOR HEREDITARY HEARING LOSS

ALPHA1-PROTEINASE INHIBITORS

NUTRIENT OR NUTRITIONAL PANEL TESTING

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

INTRAVITREAL IMPLANTS

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS

DYNAMIC SPINAL VISUALIZATION

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

DERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY

TRANSMYOCARDIAL REVASCULARIZATION

GENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS

OPTICAL COHERENCE TOMOGRAPHY (OCT) OF THE MIDDLE EAR

GENETIC TESTING FOR FANCONI ANEMIA

ENTYVIO (vedolizumab)

INTERSPINOUS FIXATION (FUSION) DEVICES

INTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS

CARDIOVASCULAR RISK PANELS

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

PERCUTANEOUS TIBIAL NERVE STIMULATION

DEEP BRAIN STIMULATION

BLINCYTO (blinatumomab)

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

STELARA (ustekinumab)

MYLOTARG (gemtuzumab ozogamicin)

GENETIC TESTING FOR NEUROFIBROMATOSIS

PERCUTANEOUS TIBIAL NERVE STIMULATION

GENETIC TESTING WITH MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES

RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE

TREATMENTS FOR GAUCHER DISEASE

CIMZIA (certolizumab pegol)

TYMLOS (abaloparatide)

APOKYN (apomorphine hydrochloride)

PERCUTANEOUS BALLOON KYPHOPLASTY, RADIOFREQUENCY KYPHOPLASTY, AND MECHANICAL VERTEBRAL AUGMENTATION

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

GATTEX (teduglutide [rdna origin])

ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA

NASAL AIRWAY EVALUATION Acoustic Reflex Technology Acoustic Rhinometry Optical Rhinometry Rhinomanometry Sleep Sonography

BRINEURA (cerliponase alfa)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

SOMATULINE DEPOT (lanreotide acetate)

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE

H.P. ACTHAR GEL (repository corticotropin injection)

PARSABIV (etelcalcetide)

BIVENTRICULAR PACEMAKER (CARDIAC RESYNCHRONIZATION THERAPY) FOR THE TREATMENT OF HEART FAILURE

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

BREAST RECONSTRUCTION/REMOVAL AND REPLACEMENT OF IMPLANTS

HEMATOPOIETIC CELL TRANSPLANTATION FOR SOLID TUMORS OF CHILDHOOD

ELECTRIC TUMOR TREATMENT FIELDS

LIMB COMPRESSION DEVICES FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

VYXEOS (daunorubicin and cytarabine)

ALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/14/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PERCUTANEOUS TRANSCATHETER CLOSURE OF PARAVALVULAR LEAK

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

INTRAOPERATIVE RADIATION THERAPY

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

TYSABRI FOR CROHN S DISEASE

BONIVA (ibandronate sodium)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

KYMRIAH (tisagenlecleucel)

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

STRENSIQ (asfotase alfa)

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEASUREMENT OF EXHALED NITRIC OXIDE AND EXHALED BREATH CONDENSATE

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

VESTIBULAR FUNCTION TESTING

COSENTYX (secukinumab)

ACTEMRA (tocilizumab)

LUXTURNA (voretigene neparovec-rzyl)

DECISIONDx BIOMARKER TESTS

YESCARTA (axicabtagene ciloleucel)

RADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS

MEDICAL POLICY SUBJECT: COGNITIVE REHABILITATION. POLICY NUMBER: CATEGORY: Therapy/Rehabilitation

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

CAROTID ARTERY ANGIOPLASTY

Transcription:

COGNITIVE THERAPY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Medical Coverage Guidelines are subject to change as new information becomes available. For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. O188.17.docx Page 1 of 7

Description: Cognitive therapy, also known as cognitive rehabilitation, is a structured set of therapeutic activities designed to retrain an individual s ability to think, use judgment and make decisions. The focus is on improving deficits in memory, attention, perception, learning, planning and judgment. The term cognitive therapy/rehabilitation is applied to various intervention strategies or techniques that attempt to help individuals reduce, manage or cope with cognitive deficits caused by a brain injury or condition. The desired outcome of this intervention is to improve quality of life or to improve ability to function in home and community life. Cognitive therapy may be performed by a physician, psychologist or a physical, occupational or speech therapist. Cognitive therapy/rehabilitation is considered a separate service from other rehabilitative therapies, with its own specific procedures. Criteria: COVERAGE FOR COGNITIVE THERAPY IS DEPENDENT UPON BENEFIT PLAN LANGUAGE. REFER TO MEMBER S SPECIFIC BENEFIT PLAN BOOKLET TO VERIFY BENEFITS. If benefit coverage for cognitive therapy is available, requests for cognitive therapy will be reviewed by the medical director(s) and/or clinical advisor(s). If benefit coverage for cognitive therapy is available, cognitive therapy is considered medically necessary with documentation of ALL of the following: 1. ONE of the following conditions, to include, but not limited to: Guillain-Barre Syndrome Medical condition that is the primary etiology of a mental dysfunction Post craniotomy Post-infectious disease pathology, e.g., meningitis, encephalitis Stroke, cerebrovascular accident (CVA) Transient ischemic attack (TIA) Traumatic or anoxic brain injury 2. Condition is considered to be non-progressive and non-degenerative 3. Rehabilitation potential exists with the expectation for clinical and functional improvement 4. Prognosis of the condition indicates a return to a prior level of function, e.g., modified independence, full independence or minimum assistance with caregiver support 5. Full participation in the evaluation process and therapy program 6. Progress in physical, occupational and speech therapies, as applicable O188.17.docx Page 2 of 7

Criteria: (cont.) If benefit coverage for cognitive therapy is available, cognitive therapy for all other indications not previously listed or if above criteria not met is considered experimental or investigational based upon: 1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 2. Insufficient evidence to support improvement of the net health outcome, and 3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives. Resources: Literature reviewed 12/19/17. We do not include marketing materials, poster boards and nonpublished literature in our review. The BCBS Association Medical Policy Reference Manual (MPRM) policy is included in our guideline review. References cited in the MPRM policy are not duplicated on this guideline. 1. 8.03.10 BCBS Association Medical Policy Reference Manual. Cognitive Rehabilitation. Re-issue date 03/09/2017 issue date 11/01/1997. 2. Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis. Expert Rev Neurother. 2008 Oct 2008;8(10):1585-1596. 3. Babiloni C, Del Percio C, Valenzano A, et al. Frontal attentional responses to food size are abnormal in obese subjects: an electroencephalographic study. Clin Neurophysiol. 2009 Aug 2009;120(8):1441-1448. 4. Bayley MT, Hurdowar A, Teasell R, et al. Priorities for stroke rehabilitation and research: results of a 2003 Canadian Stroke Network consensus conference. Arch Phys Med Rehabil. 2007 Apr 2007;88(4):526-528. 5. Bergquist T, Gehl C, Lepore S, Holzworth N, Beaulieu W. Internet-based cognitive rehabilitation in individuals with acquired brain injury: a pilot feasibility study. Brain Inj. 2008 Oct 2008;22(11):891-897. O188.17.docx Page 3 of 7

Resources: (cont.) 6. Bornhofen C, Mcdonald S. Treating deficits in emotion perception following traumatic brain injury. Neuropsychol Rehabil. 2008 Jan 2008;18(1):22-44. 7. Bouwens SF, van Heugten CM, Verhey FR. The practical use of goal attainment scaling for people with acquired brain injury who receive cognitive rehabilitation. Clin Rehabil. 2009 Apr 2009;23(4):310-320. 8. Bowen A, Lincoln NB. Cognitive rehabilitation for spatial neglect following stroke. Cochrane Database Syst Rev. 2007 2007(2):CD003586. 9. Buiza C, Etxeberria I, Galdona N, et al. A randomized, two-year study of the efficacy of cognitive intervention on elderly people: the Donostia Longitudinal Study. Int J Geriatr Psychiatry. 2007 May 25 2007. 10. Buiza C, Etxeberria I, Galdona N, et al. A randomized, two-year study of the efficacy of cognitive intervention on elderly people: the Donostia Longitudinal Study. Int J Geriatr Psychiatry. 2008 Jan 2008;23(1):85-94. 11. Cicerone KD, Azulay J. Perceived self-efficacy and life satisfaction after traumatic brain injury. J Head Trauma Rehabil. 2007 Sep-Oct 2007;22(5):257-266. 12. Claypoole KH, Noonan C, Mahurin RK, Goldberg J, Erickson T, Buchwald D. A twin study of cognitive function in chronic fatigue syndrome: The effects of sudden illness onset. Neuropsychology. 2007 Jul 2007;21(4):507-513. 13. Constantinidou F, Thomas RD, Robinson L. Benefits of categorization training in patients with traumatic brain injury during post-acute rehabilitation: additional evidence from a randomized controlled trial. J Head Trauma Rehabil. 2008 Sep-Oct 2008;23(5):312-328. 14. Craik FI, Winocur G, Palmer H, et al. Cognitive rehabilitation in the elderly: effects on memory. J Int Neuropsychol Soc. 2007 Jan 2007;13(1):132-142. 15. Flanagan SR, Cantor JB, Ashman TA. Traumatic brain injury: future assessment tools and treatment prospects. Neuropsychiatr Dis Treat. 2008 Oct 2008;4(5):877-892. 16. Goverover Y, Chiaravalloti N, DeLuca J. Self-generation to improve learning and memory of functional activities in persons with multiple sclerosis: meal preparation and managing finances. Arch Phys Med Rehabil. 2008 Aug 2008;89(8):1514-1521. O188.17.docx Page 4 of 7

Resources: (cont.) 17. Levine B, Stuss DT, Winocur G, et al. Cognitive rehabilitation in the elderly: effects on strategic behavior in relation to goal management. J Int Neuropsychol Soc. 2007 Jan 2007;13(1):143-152. 18. Mateer CA, Sira CS. Cognitive and emotional consequences of TBI: intervention strategies for vocational rehabilitation. NeuroRehabilitation. 2006 2006;21(4):315-326. 19. McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A. Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry. 2007 Mar 2007;164(3):437-441. 20. New Zealand Guidelines Group. Traumatic Brain Injury Diagnosis, Acute Management and Rehabilitation. 2006. 21. O'Brien AR, Chiaravalloti N, Goverover Y, Deluca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil. 2008 Apr 2008;89(4):761-769. 22. Palmer SL, Reddick WE, Gajjar A. Understanding the cognitive impact on children who are treated for medulloblastoma. J Pediatr Psychol. 2007 Oct 2007;32(9):1040-1049. 23. Penner IK, Opwis K, Kappos L. Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. J Neurol. 2007 May 2007;254 Suppl 2:II53-II57. 24. Raggi A, Iannaccone S, Marcone A, et al. The effects of a comprehensive rehabilitation program of Alzheimer's Disease in a hospital setting. Behav Neurol. 2007 2007;18(1):1-6. 25. Winocur G, Palmer H, Dawson D, Binns MA, Bridges K, Stuss DT. Cognitive rehabilitation in the elderly: an evaluation of psychosocial factors. J Int Neuropsychol Soc. 2007 Jan 2007;13(1):153-165. O188.17.docx Page 5 of 7

Non-Discrimination Statement: Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services. If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ s Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ s Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1 800 368 1019, 800 537 7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Multi-Language Interpreter Services: O188.17.docx Page 6 of 7

Multi-Language Interpreter Services: (cont.) O188.17.docx Page 7 of 7